Business Description
Tonix Pharmaceuticals Holding Corp
NAICS : 325412
SIC : 2834
ISIN : US8902608392
Total Employee Number:
142Compare
Compare
Traded in other countries / regions
TNXP.USATPM0.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2009-02-13Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 138.55 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.24 | |||||
Beneish M-Score | -0.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 93.6 | |||||
3-Year EPS without NRI Growth Rate | 93.9 | |||||
3-Year FCF Growth Rate | 94.5 | |||||
3-Year Book Growth Rate | -92.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 32.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 124.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.51 | |||||
9-Day RSI | 59.86 | |||||
14-Day RSI | 57.05 | |||||
3-1 Month Momentum % | -17.43 | |||||
6-1 Month Momentum % | -17.66 | |||||
12-1 Month Momentum % | -67.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.61 | |||||
Quick Ratio | 6.42 | |||||
Cash Ratio | 5.72 | |||||
Days Inventory | 450.64 | |||||
Days Sales Outstanding | 82.02 | |||||
Days Payable | 669.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1373.2 | |||||
Shareholder Yield % | -94.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.83 | |||||
Operating Margin % | -562.75 | |||||
Net Margin % | -548.64 | |||||
EBITDA Margin % | -550.72 | |||||
FCF Margin % | -536.38 | |||||
OCF Margin % | -525.71 | |||||
ROE % | -72.99 | |||||
ROA % | -64.96 | |||||
ROIC % | -284.66 | |||||
3-Year ROIIC % | 26.62 | |||||
ROC (Joel Greenblatt) % | -362.21 | |||||
ROCE % | -73.98 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.86 | |||||
PB Ratio | 0.95 | |||||
Price-to-Tangible-Book | 0.95 | |||||
EV-to-EBIT | -0.25 | |||||
EV-to-EBITDA | -0.25 | |||||
EV-to-Revenue | 1.38 | |||||
EV-to-Forward-Revenue | 1.22 | |||||
EV-to-FCF | -0.26 | |||||
Price-to-GF-Value | 4.03 | |||||
| Price-to-Net-Current-Asset-Value | 1.23 | |||||
| Price-to-Net-Cash | 1.46 | |||||
Earnings Yield (Greenblatt) % | -400 | |||||
FCF Yield % | -72.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TNXP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tonix Pharmaceuticals Holding Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29.102 | ||
| EPS (TTM) ($) | -12.94 | ||
| Beta | -0.7344 | ||
| 3-Year Sharpe Ratio | -0.41 | ||
| 3-Year Sortino Ratio | -0.64 | ||
| Volatility % | 38.71 | ||
| 14-Day RSI | 57.05 | ||
| 14-Day ATR ($) | 0.803289 | ||
| 20-Day SMA ($) | 11.59125 | ||
| 12-1 Month Momentum % | -67.75 | ||
| 52-Week Range ($) | 9.4 - 39.45 | ||
| Shares Outstanding (Mil) | 17.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tonix Pharmaceuticals Holding Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tonix Pharmaceuticals Holding Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 79 days | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 13:30 | 12.59 (+8.35%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 08:30 | 12.03 (+2.12%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 12.03 (+2.12%) | ||
| A.G.P.\'s Annual Virtual Healthcare Conference | 2026-05-20 15:00 | 13.71 (-1.65%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-19 13:35 | 14.26 (-9.63%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 14.09 (+2.85%) | ||
| General meeting for 2026 | 2026-05-07 11:00 | 14.69 (+3.45%) | ||
| Annual report for 2025 | 2026-03-12 | 13.98 (-0.21%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 13.98 (-0.21%) |
Show
Entries
Tonix Pharmaceuticals Holding Corp Frequently Asked Questions
What is Tonix Pharmaceuticals Holding Corp(TNXP)'s stock price today?
The current price of TNXP is $12.54. The 52 week high of TNXP is $39.45 and 52 week low is $9.40.
When is next earnings date of Tonix Pharmaceuticals Holding Corp(TNXP)?
The next earnings date of Tonix Pharmaceuticals Holding Corp(TNXP) is 2026-11-10 Est..
Does Tonix Pharmaceuticals Holding Corp(TNXP) pay dividends? If so, how much?
Tonix Pharmaceuticals Holding Corp(TNXP) does not pay dividend.
Press Release
Articles on Tonix Pharmaceuticals Holding Corp
Headlines
See More- 1
Aug 10, 2026
Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September
Seeking Alpha • 11:59am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers